contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


curasight-klar-til-naeste-kliniske-fase-pipeline-styrket-af-kapitaltilforsel

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

Selskabet fik styrket sit kapitalberedskab i Q2, og efter kvartalets afslutning har Curasight fået grønt lys til sit fase 1-forsøg (Proof-of-Concept) med uTREAT® hos hjernetumorpatienter (glioblastom).

Selskabet fik styrket sit kapitalberedskab i Q2, og efter kvartalets afslutning har Curasight f&#xe5;et gr&#xf8;nt lys til sit fase 1-fors&#xf8;g (Proof-of-Concept) med uTREAT&#xae; hos hjernetumorpatienter (glioblastom).
Curasights CEO, Ulrich Krasilnikoff, udtaler:&#xa0;&#x201d;I andet kvartal af 2025 gennemf&#xf8;rte vi med stor tilfredshed en kapitaltilf&#xf8;rsel p&#xe5; cirka 65 mio. DKK, best&#xe5;ende af kapital fra nye investorer samt nye og genforhandlede l&#xe5;n. Med den styrkede finansielle position st&#xe5;r vi nu endnu bedre rustet til at realisere vores theranostiske strategi, hvor vi gennem radiofarmaceutiske l&#xf8;sninger udvikler mere sk&#xe5;nsom og m&#xe5;lrettet diagnosticering og behandling af udvalgte kr&#xe6;ftformer. Kapitalgrundlaget g&#xf8;r det muligt at accelerere b&#xe5;de fase II-studiet med vores uTRACE&#xae;-diagnostiske platform inden for prostatakr&#xe6;ft samt fase I-studiet med uTREAT&#xae; i glioblastom &#x2013; et omr&#xe5;de, hvor vi netop har f&#xe5;et gr&#xf8;nt lys fra Det Europ&#xe6;iske L&#xe6;gemiddelagentur til at igangs&#xe6;tte studiet og p&#xe5;begynde patientinkludering. Vi ser frem til at skabe yderligere v&#xe6;rdi gennem disse vigtige kliniske milep&#xe6;le.&#x201d;
Selskabet giver ingen finansiel guidance for 2025.
Q2 regnskab 2025 vs. 2024:
<img src="https://content.inderes.se/assets/094578de-0337-4f7e-8cdd-7f982c723e03.png?width=687&amp;height=346" alt="Curasight Q2 2025 Vs 2024">
Curasights driftsresultat forv&#xe6;rres YoY som f&#xf8;lge af &#xf8;get pipeline-aktivitet, men soliditeten er styrket som f&#xf8;lge af tilf&#xf8;rt kapital
L&#xe6;s hele regnskabet her: <a href="https://news.cision.com/curasight/r/half-year-report-q2-2025,c4225556" target="_blank" rel="noopener">Q2 og halv&#xe5;rsregnskab</a>
Deltag p&#xe5; dagens regnskabspr&#xe6;sentation med CEO Ulrich Krasilnikoff og CSO Andreas Kj&#xe6;r her: <a href="https://www.inderes.dk/videos/curasight-praesentation-af-halvarsregnskabet-for-2025" target="_blank" rel="noopener">Curasight regnskabspr&#xe6;sentation kl 13:30</a>
Disclaimer: HC Andersen Capital modtager betaling fra Curasight for en Digital IR abonnementsaftale. Claus Thestrup kl. 8:00 d. 28-08-2025.

HC Andersen Capital

Curasight: Klar til næste kliniske fase – pipeline styrket af kapitaltilførsel